REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
13

Starting Compounded Semaglutide — Protocol Check

Mae Armstrong·25 days ago
About to start Compounded Semaglutide and wanted to share my planned protocol for community feedback before diving in. I have spent the last month researching and consulting with others who have experience. Planned approach: I am going with a gradual titration over the first 10 days, starting at roughly half the target dose and increasing by about 20 percent every 3 days until I reach the full amount. This should help me assess tolerance without committing to a full dose from day one. Timing: morning administration, fasted. I chose this based on the majority of positive reports I have read. Will reconsider if I experience any energy disruption in the evening. Duration: planning 10 weeks for the first run. I have pre-scheduled bloodwork at baseline, week 5, and week 10. Support protocol: I am maintaining my current supplement stack (magnesium, vitamin D, omega-3) and keeping training volume constant so I can isolate the effects of Compounded Semaglutide specifically. Would appreciate any input from those who have run similar protocols. Anything you wish you had known before starting?

Comments (4)

Micah CassidyDEMO·25 days ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Compounded Semaglutide protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

6
Bailey CraneDEMO·25 days ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Compounded Semaglutide journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

2
London DarcyDEMO·25 days ago

This is a great discussion about Compounded Semaglutide. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

3
Shiloh BatesDEMO·25 days ago

Thanks for sharing the science behind Compounded Semaglutide. I think the mechanism explanation really helps people understand why patience is necessary with these protocols. It is not like taking a painkiller where you feel effects in 30 minutes — you are initiating biological programs that take weeks to fully manifest.

4

Sign in to comment.